Apellis
Manufacturing · Massachusetts, United States · 476 Employees
Who is Apellis
Established in 2009, Apellis is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. They are based in Waltham, Massachusetts.Read More
Headquarters:
100 5th Avenue, Waltham, Massachusetts, 02451, United States
Phone Number:
(617) 977-5700
Revenue:
$256 Million
Stock Symbol:
APLS
Apellis's Social Media
Popular Searches:
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc.
APELLIS PHARMACEUTICALS , INC.
Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc.
Top Competitors of Apellis
Apellis's Org Chart
Phone
Email
Apellis Company Metrics
Funding
| Funding Date | Round | Amount | Investors | |
|---|---|---|---|---|
Nov 19, 2021 | Stock Issuance/Offering | $402M | - | |
Nov 10, 2017 | Stock Issuance/Offering | $150M | - | |
Aug 10, 2017 | Series E | $60M | Clough Capital Partners | + 9 more  |
See More
$721M
Total Funding Amount
$402M
Most Recent Funding Amount
9
Number of Funding Rounds
Revenue
| Quarter | Revenue |
|---|---|
'21 - Q1 | 288015000 |
'21 - Q2 | 288015000 |
Acquisitions & Subsidiaries
Potentia Pharmaceuticals
See More Acquisitions & Subsidiaries
Apellis's Tech Stack
Apellis News & Media
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson Sells ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Rating) General Counsel David O. Watson sold 10,000 shares of the business's stock in a transaction dated Wednesday, June 22nd. The stock was sold at an average price of $44.51, for a total transaction of $445,100.00. Following the sale, the general counsel now directly owns 115,569 shares in the company, valued at approximately $5,143,976.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which
Jun 24, 2022Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain
WALTHAM, Mass. and NANTES, France, June 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Affilogic today announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins® targeting the transferrin receptor (TfR), which enables drugs to be transported across the blood brain barrier and into the central nervous system. TfR-specific Nanofitins, also known as brainJun 22, 2022New data reinforce robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for PNH at the EHA2022 Congress
Swedish Orphan Biovitrum AB (publ) (Sobi (https://www.sobi.com/en/media)®) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today reported new analyses of phase 3 studies that reinforce the robust efficacy and safety profile of Aspaveli®/Empaveli® (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria (PNH). The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria. New analyses demonstrated that treatment with Aspaveli/Empaveli resulJun 10, 2022Subscribe to "Apellis" News
Frequently Asked Questions regarding Apellis
Where are Apellis’s headquarters?
Apellis’s headquarters are in 100 5th Avenue, Waltham, Massachusetts, 02451, United States
What is Apellis’s phone number?
Apellis’s phone number is (617) 977-5700
What is Apellis’s stock symbol?
Apellis’s stock symbol is APLS
What is Apellis’s official website?
Apellis’s official website is www.apellis.com
What is Apellis’s Revenue?
Apellis’s revenue is $256 Million
What is Apellis’s SIC code?
Apellis’s SIC: 28,283
What is Apellis’s NAICS code?
Apellis’s NAICS: 3254,541714
How many employees are working in Apellis?
Apellis has 476 employees
What is Apellis’s industry?
Apellis is in the industry of: Manufacturing, Pharmaceuticals, Business Services
Who are Apellis’s main competitors?
Apellis's main competitors are: Atara Bio, Stealth BioTherapeutics, Tessa Therapeutics, Otonomy
What companies has Apellis acquired?
Apellis has acquired the companies: Potentia Pharmaceuticals
What is Apellis's tech stack?
The technologies that are used by Apellis are: QuickBooks, NetSuite, Achievers, Cvent
Who is Apellis's CEO?
Apellis's CEO is Cedric Francois
Who is Apellis's CFO?
Apellis's CFO is Timothy Sullivan
Who is Apellis's CTO?
Apellis's CTO is Pascal Deschatelets
Slide to rate Cedric Francois as a Co-Founder, Chief Executive Officer & President
4.4/5 on G2 Crowd
Test Drive ZoomInfo's Directories
Browse Directories
